{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:15:44Z","timestamp":1790709344743,"version":"4.1.0"},"reference-count":235,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic pruritus that lasts for over 6 weeks can present in various forms, like papules, nodules, and plaque types, with prurigo nodularis (PN) being the most prevalent. The pathogenesis of PN involves the dysregulation of immune cell\u2013neural circuits and is associated with peripheral neuropathies, possibly due to chronic scratching. PN is a persistent and challenging condition, involving complex interactions among the skin, immune system, and nervous system. Lesional skin in PN exhibits the infiltration of diverse immune cells like T cells, eosinophils, macrophages, and mast cells, leading to the release of inflammatory cytokines and itch-inducing substances. Activated sensory nerve fibers aggravate pruritus by releasing neurotransmitters, perpetuating a vicious cycle of itching and scratching. Traditional treatments often fail, but recent advancements in understanding the inflammatory and itch transmission mechanisms of PN have paved the way for innovative therapeutic approaches, which are explored in this review.<\/jats:p>","DOI":"10.3390\/ijms25105164","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:21:04Z","timestamp":1715311264000},"page":"5164","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics"],"prefix":"10.3390","volume":"25","author":[{"given":"Hwa Jung","family":"Yook","sequence":"first","affiliation":[{"name":"Department of Dermatology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, #222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-502X","authenticated-orcid":false,"given":"Ji Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, #222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.21698","article-title":"Chronic prurigo","volume":"187","author":"Misery","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/j.pain.0000000000001220","article-title":"Alloknesis and hyperknesis-mechanisms, assessment methodology, and clinical implications of itch sensitization","volume":"159","author":"Andersen","year":"2018","journal-title":"Pain"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jdv.14570","article-title":"European academy of dermatology and venereology European prurigo project: Expert consensus on the definition, classification and terminology of chronic prurigo","volume":"32","author":"Pereira","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"649332","DOI":"10.3389\/fmed.2021.649332","article-title":"Chronic Prurigo: Similar Clinical Profile and Burden Across Clinical Phenotypes","volume":"8","author":"Zeidler","year":"2021","journal-title":"Front. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus","volume":"84","author":"Elmariah","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: Targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/itx.0000000000000042","article-title":"IFSI-guideline on chronic prurigo including prurigo nodularis","volume":"5","author":"Pereira","year":"2020","journal-title":"Itch"},{"key":"ref_8","first-page":"e414","article-title":"2020 guidelines for the diagnosis and treatment of prurigo","volume":"48","author":"Satoh","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","article-title":"Prurigo nodularis: Epidemiology and clinical features","volume":"83","author":"Huang","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMe1916733","article-title":"Breaking the Itch-Scratch Cycle in Prurigo Nodularis","volume":"382","author":"Kwatra","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2133.2011.10306.x","article-title":"Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy","volume":"165","author":"Schuhknecht","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: Pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1016\/j.jaip.2020.05.051","article-title":"Prevalence of prurigo nodularis in the United States","volume":"8","author":"Whang","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.jid.2021.02.756","article-title":"A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States","volume":"141","author":"Wongvibulsin","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jaad.2021.09.028","article-title":"Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study","volume":"86","author":"Sutaria","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Whang, K.A., Khanna, R., Thomas, J., Aguh, C., and Kwatra, S.G. (2019). Racial and Gender Differences in the Presentation of Pruritus. Medicines, 6.","DOI":"10.3390\/medicines6040098"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1111\/jdv.17485","article-title":"Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population-based claims data analysis","volume":"35","author":"Augustin","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"adv00781","DOI":"10.2340\/actadv.v102.2227","article-title":"Impact of Chronic Kidney Disease Severity on the Risk of Prurigo Nodularis: A Population-Based Cohort Study","volume":"102","author":"Kim","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Woo, Y.R., Wang, S., Sohn, K.A., and Kim, H.S. (2021). Epidemiology, Comorbidities, and Prescription Patterns of Korean Prurigo Nodularis Patients: A Multi-Institution Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010095"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Whang, K.A., Kang, S., and Kwatra, S.G. (2019). Inpatient Burden of Prurigo Nodularis in the United States. Medicines, 6.","DOI":"10.3390\/medicines6030088"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"adv00155","DOI":"10.2340\/00015555-3518","article-title":"Prevalence of Prurigo Nodularis in Poland","volume":"100","author":"Ryczek","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0009922808321899","article-title":"Prurigo nodularis in a 9-year-old girl","volume":"48","author":"Amer","year":"2009","journal-title":"Clin. Pediatr. (Phila)"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2133.1985.tb02357.x","article-title":"Nodular prurigo--a clinicopathological study of 46 patients","volume":"113","author":"Wilkinson","year":"1985","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000358250","article-title":"Extensive prurigo nodularis: Characterization and etiology","volume":"228","author":"Tan","year":"2014","journal-title":"Dermatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2340\/00015555-2774","article-title":"Chronic Prurigo of Nodular Type: A Review","volume":"98","author":"Zeidler","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaci.2021.09.015","article-title":"Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations","volume":"148","author":"Croce","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.jaip.2023.05.014","article-title":"Racial and ethnic disparities in the treatment of patients with atopic dermatitis in the United States: A retrospective matched cohort study","volume":"11","author":"Craig","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1111\/jdv.17756","article-title":"Clinical characteristics of chronic nodular prurigo are independent of Fitzpatrick skin type: A European prospective cross-sectional study","volume":"36","author":"Pereira","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.jid.2023.04.033","article-title":"A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis","volume":"143","author":"Vasavda","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2174\/0929867043364748","article-title":"Tachykinins and tachykinin receptors: Structure and activity relationships","volume":"11","author":"Almeida","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.det.2018.02.003","article-title":"Prurigo Nodularis and Its Management","volume":"36","author":"Zeidler","year":"2018","journal-title":"Dermatol. Clin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00105-014-2754-y","article-title":"Pathogenesis of prurigo nodularis","volume":"65","author":"Raap","year":"2014","journal-title":"Hautarzt"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s004030000142","article-title":"Eosinophil cationic protein- and eosinophil-derived neurotoxin\/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis","volume":"292","author":"Johansson","year":"2000","journal-title":"Arch. Dermatol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1440-0960.2005.00187.x","article-title":"Prurigo nodularis: A review","volume":"46","author":"Lee","year":"2005","journal-title":"Australas. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1600-0560.1998.tb01718.x","article-title":"Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: A reappraisal","volume":"25","author":"Liang","year":"1998","journal-title":"J. Cutan. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: A new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/exd.14279","article-title":"Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta","volume":"30","author":"Hashimoto","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0625.2008.00766.x","article-title":"Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC\/Nga mice: A model of atopic dermatitis","volume":"18","author":"Grimstad","year":"2009","journal-title":"Exp. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.jid.2022.02.010","article-title":"Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis","volume":"142","author":"Sutaria","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1684\/ejd.2010.1196","article-title":"Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo","volume":"21","author":"Park","year":"2011","journal-title":"Eur. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1011142","DOI":"10.3389\/fmed.2022.1011142","article-title":"Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis","volume":"9","author":"Parthasarathy","year":"2022","journal-title":"Front. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1301817","DOI":"10.3389\/fimmu.2023.1301817","article-title":"Molecular mechanisms of pruritus in prurigo nodularis","volume":"14","author":"Shao","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cytogfr.2015.07.006","article-title":"Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology","volume":"26","author":"Hermanns","year":"2015","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1067\/mai.2000.107604","article-title":"IL-4\/IL-13 signaling beyond JAK\/STAT","volume":"105","author":"Jiang","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ajpath.2011.11.031","article-title":"VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression","volume":"180","author":"Wang","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1111\/jocd.14709","article-title":"A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications","volume":"21","author":"Agrawal","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4103\/ijd.ijd_341_21","article-title":"A Prospective Study Examining the Effect of Selected Topical and Systemic Drugs on Pruritus Grading System Score and STAT 6 Expression in Patients of Prurigo Nodularis","volume":"66","author":"Agrawal","year":"2021","journal-title":"Indian J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2011.10498.x","article-title":"Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis","volume":"165","author":"Fukushi","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaad.2020.03.049","article-title":"Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo","volume":"83","author":"Chiricozzi","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/exd.14034","article-title":"Interleukin-4 and interleukin-13 evoke scratching behaviour in mice","volume":"28","author":"Campion","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00403-019-01972-3","article-title":"The IL-4\/IL-13 axis in skin fibrosis and scarring: Mechanistic concepts and therapeutic targets","volume":"312","author":"Nguyen","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14712598.2021.1958777","article-title":"Therapeutic potential of biologics in prurigo nodularis","volume":"22","author":"Muller","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jid.2019.12.011","article-title":"The Return of the Mast Cell: New Roles in Neuroimmune Itch Biology","volume":"140","author":"Wang","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jaci.2022.02.021","article-title":"Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: From mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2990.2010.01089.x","article-title":"Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum","volume":"36","author":"Muller","year":"2010","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yang, H., Chen, W., Zhu, R., Wang, J., and Meng, J. (2022). Critical Players and Therapeutic Targets in Chronic Itch. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179935"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"48448","DOI":"10.7554\/eLife.48448","article-title":"Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis","volume":"8","author":"Walsh","year":"2019","journal-title":"Elife"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jid.2022.08.042","article-title":"Transcriptomic, Epigenomic, and Neuroanatomic Signatures Differ in Chronic Prurigo, Atopic Dermatitis, and Brachioradial Pruritus","volume":"143","author":"Agelopoulos","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/exd.13343","article-title":"There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations","volume":"26","author":"Pereira","year":"2017","journal-title":"Exp. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2340\/00015555-2232","article-title":"Intraepidermal Nerve Fibre Density is Decreased in Lesional and Inter-lesional Prurigo Nodularis and Reconstitutes on Healing of Lesions","volume":"96","author":"Bobko","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1111\/jdv.18942","article-title":"Increased sensitivity to touch-evoked itch (punctate hyperknesis) in prurigo nodularis and type 2 inflammation: A cross-sectional pilot study","volume":"37","author":"Hashimoto","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jid.2019.05.029","article-title":"Peripheral Sensitization and Loss of Descending Inhibition Is a Hallmark of Chronic Pruritus","volume":"140","author":"Pereira","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/bjd\/ljad121","article-title":"Prurigo nodularis is highly linked with neural sensitization disorders of pain among hospitalized adults in the United States\u2014National Inpatient Sample 2016\u20132019","volume":"189","author":"Choragudi","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2340\/00015555-3261","article-title":"Selective Nerve Fibre Activation in Patients with Generalized Chronic Pruritus: Hint for Central Sensitization?","volume":"99","author":"Pereira","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI124609","article-title":"Neuro-immune crosstalk and allergic inflammation","volume":"129","author":"Kabata","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2340\/00015555-2780","article-title":"Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant","volume":"98","author":"Ohanyan","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jdermsci.2010.03.020","article-title":"Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis","volume":"58","author":"Haas","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/exd.14014","article-title":"Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus","volume":"28","author":"Nakashima","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaci.2023.05.004","article-title":"Basic mechanisms of itch","volume":"152","author":"Misery","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"108355","DOI":"10.1016\/j.pharmthera.2023.108355","article-title":"How to get rid of itching","volume":"243","author":"Ju","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaad.2021.07.078","article-title":"Itch: Pathogenesis and treatment","volume":"86","author":"Sutaria","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12264-017-0200-8","article-title":"Regulation of Pain and Itch by TRP Channels","volume":"34","author":"Moore","year":"2018","journal-title":"Neurosci. Bull."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.0906-6705.2004.0178.x","article-title":"Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures","volume":"13","author":"Stander","year":"2004","journal-title":"Exp. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"107472","DOI":"10.1016\/j.celrep.2020.03.036","article-title":"Periostin Activation of Integrin Receptors on Sensory Neurons Induces Allergic Itch","volume":"31","author":"Mishra","year":"2020","journal-title":"Cell Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.4049\/jimmunol.1300300","article-title":"TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis","volume":"191","author":"Oh","year":"2013","journal-title":"J. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neulet.2011.02.009","article-title":"Role of transient receptor potential ankyrin subfamily member 1 in pruritus induced by endothelin-1","volume":"492","author":"Liang","year":"2011","journal-title":"Neurosci. Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nn.2789","article-title":"TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch","volume":"14","author":"Wilson","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1038\/sj.emboj.7600893","article-title":"NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels","volume":"24","author":"Zhang","year":"2005","journal-title":"EMBO J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jaci.2021.10.004","article-title":"Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab","volume":"149","author":"Tsoi","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.jid.2021.02.749","article-title":"Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization","volume":"141","author":"Belzberg","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial","volume":"78","author":"Brunner","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjd.12943","article-title":"Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis","volume":"171","author":"Kou","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/exd.14678","article-title":"RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching","volume":"32","author":"Shao","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/exd.14389","article-title":"Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease","volume":"30","author":"Sims","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jaci.2023.04.019","article-title":"Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis","volume":"152","author":"Alkon","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaci.2023.07.005","article-title":"Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab","volume":"153","author":"Ma","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jaci.2023.11.003","article-title":"Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis","volume":"153","author":"Conrad","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Patel, J.R., Joel, M.Z., Lee, K.K., Kambala, A., Cornman, H., Oladipo, O., Taylor, M., Deng, J., Parthasarathy, V., and Cravero, K. (2023). Single-cell RNA sequencing reveals dysregulated fibroblast subclusters in prurigo nodularis. bioRxiv.","DOI":"10.1101\/2023.01.29.526050"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Kwon, C.D., Khanna, R., Williams, K.A., Kwatra, M.M., and Kwatra, S.G. (2019). Diagnostic Workup and Evaluation of Patients with Prurigo Nodularis. Medicines, 6.","DOI":"10.3390\/medicines6040097"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/09546634.2013.814759","article-title":"Prurigo nodularis: An update on etiopathogenesis and therapy","volume":"24","author":"Fostini","year":"2013","journal-title":"J. Dermatol. Treat."},{"key":"ref_103","unstructured":"Kang, S., Amagai, M., Bruckner, A.L., Enk, A.H., Margolis, D.J., McMichael, A.J., and Orringer, J.S. (2019). Fitzpatrick\u2019s Dermatology, McaGraw-Hill. [9th ed.]."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","article-title":"Prurigo nodularis: Systematic analysis of 58 histological criteria in 136 patients","volume":"37","author":"Weigelt","year":"2010","journal-title":"J. Cutan. Pathol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2023.04.018","article-title":"Clinical aspects and management of chronic itch","volume":"152","author":"Zeidler","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/jdv.13296","article-title":"European EADV network on assessment of severity and burden of Pruritus (PruNet): First meeting on outcome tools","volume":"30","author":"Stander","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/jdv.17111","article-title":"Pruritus Intensity Scales across Europe: A prospective validation study","volume":"35","author":"Storck","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2016.08.009","article-title":"Assessment of severity and burden of pruritus","volume":"66","author":"Pereira","year":"2017","journal-title":"Allergol. Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1111\/jdv.13827","article-title":"Anxiety, depression and suicide in patients with prurigo nodularis","volume":"31","author":"Jorgensen","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"adv00403","DOI":"10.2340\/00015555-3726","article-title":"Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction","volume":"101","author":"Pereira","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/jdv.16929","article-title":"The burden in chronic prurigo: Patients with chronic prurigo suffer more than patients with chronic pruritus on non-lesional skin: A comparative, retrospective, explorative statistical analysis of 4484 patients in a real-world cohort","volume":"35","author":"Zeidler","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2133.2005.06852.x","article-title":"Psychological factors in prurigo nodularis in comparison with psoriasis vulgaris: Results of a case-control study","volume":"154","author":"Schneider","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaad.2013.12.015","article-title":"Chronic pruritus in HIV-positive patients in the southeastern United States: Its prevalence and effect on quality of life","volume":"70","author":"Kaushik","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.trstmh.2011.04.001","article-title":"Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana","volume":"105","author":"Magand","year":"2011","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1046\/j.1365-4362.1998.00507.x","article-title":"Prurigo nodularis in HIV-infected individuals","volume":"37","author":"Matthews","year":"1998","journal-title":"Int. J. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/1346-8138.12408","article-title":"Persistent prurigo nodularis in HIV-infected patient responsive to antiretroviral therapy with raltegravir","volume":"41","author":"Motegi","year":"2014","journal-title":"J. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/archdermatol.2010.128","article-title":"Persistent prurigo nodularis responsive to initiation of combination therapy with raltegravir","volume":"146","author":"Unemori","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2340\/00015555-1209","article-title":"Prurigo nodularis in hepatitis C infection: Result of an occupational disease?","volume":"92","author":"Weisshaar","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0168-8278(98)80216-X","article-title":"Hyde\u2019s prurigo nodularis and chronic HCV hepatitis","volume":"28","author":"Neri","year":"1998","journal-title":"J. Hepatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/archderm.1995.01690190108029","article-title":"Association of prurigo with hepatitis C virus infection","volume":"131","author":"Kanazawa","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_121","first-page":"2281","article-title":"Prurigo nodularis (Hyde\u2019s prurigo) disclosing celiac disease","volume":"46","author":"Resta","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"ref_122","first-page":"89","article-title":"Prurigo nodularis and gluten enteropathy","volume":"95","author":"McKenzie","year":"1976","journal-title":"Br. J. Dermatol."},{"key":"ref_123","first-page":"140","article-title":"Nodular prurigo assiciated with gluten enteropathy","volume":"70","author":"Goodwin","year":"1977","journal-title":"Proc. R. Soc. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/abd1806-4841.20187127","article-title":"Xerosis cutis and associated co-factors in women with prurigo nodularis","volume":"93","author":"Akarsu","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non-atopic diseases: Aetiological survey in a consecutive cohort of 108 patients","volume":"27","author":"Iking","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/1346-8138.14106","article-title":"Generalized eruptive keratoacanthoma with vitiligo followed by the development of prurigo nodularis: A case report and published work review","volume":"45","author":"Xu","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaad.2013.03.035","article-title":"Keratoacanthomas arising in association with prurigo nodules in pruritic, actinically damaged skin","volume":"69","author":"Wu","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0190-9622(86)70117-5","article-title":"Bullous pemphigoid and prurigo nodularis","volume":"14","author":"Roenigk","year":"1986","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2133.2006.07315.x","article-title":"Linear IgA disease presenting as prurigo nodularis","volume":"155","author":"Torchia","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/ijd.12022","article-title":"Prurigo nodularis as index symptom of (non-Hodgkin) lymphoma: Ultrasound as a helpful diagnostic tool in dermatological disorders of unknown origin","volume":"54","author":"Schweda","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1525-1470.1990.tb00670.x","article-title":"Hodgkin\u2019s disease manifesting as prurigo nodularis","volume":"7","author":"Shelnitz","year":"1990","journal-title":"Pediatr. Dermatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-4632.2006.02675.x","article-title":"Cutaneous manifestations of Hodgkin\u2019s disease","volume":"45","author":"Rubenstein","year":"2006","journal-title":"Int. J. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jaad.2019.03.083","article-title":"Association between prurigo nodularis and malignancy in middle-aged adults","volume":"81","author":"Larson","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_134","first-page":"203","article-title":"Nodular Prurigo Associated with Mycosis Fungoides\u2014Case Report","volume":"23","author":"Ceovic","year":"2015","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1346-8138.1996.tb02684.x","article-title":"Prurigo nodularis associated with advanced gastric cancer: Report of a case","volume":"23","author":"Funaki","year":"1996","journal-title":"J. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2230.2006.02310.x","article-title":"Nodular prurigo: Metabolic diseases are a common association","volume":"32","author":"Winhoven","year":"2007","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/CCID.S188070","article-title":"Treatment-resistant prurigo nodularis: Challenges and solutions","volume":"12","author":"Kowalski","year":"2019","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_138","first-page":"e5256","article-title":"Pruritus Associated With Chronic Kidney Disease: A Comprehensive Literature Review","volume":"11","author":"Swarna","year":"2019","journal-title":"Cureus"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/IJNRD.S108045","article-title":"Chronic kidney disease-associated pruritus: Impact on quality of life and current management challenges","volume":"10","author":"Shirazian","year":"2017","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.semnephrol.2015.06.009","article-title":"Pruritus in Kidney Disease","volume":"35","author":"Combs","year":"2015","journal-title":"Semin. Nephrol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Carstens, E., and Akiyama, T. (2014). Itch: Mechanisms and Treatment, CRC Press\/Taylor & Francis. Frontiers in Neuroscience.","DOI":"10.1201\/b16573"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","article-title":"Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality","volume":"145","author":"Prodanovich","year":"2009","journal-title":"Arch. Dermatol."},{"key":"ref_143","first-page":"221","article-title":"Prurigo nodularis: Picking the right treatment","volume":"64","author":"Saco","year":"2015","journal-title":"J. Fam. Pract."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2019.07.022","article-title":"Diagnostic and treatment algorithm for chronic nodular prurigo","volume":"82","author":"Stander","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaad.2019.09.007","article-title":"Analysis of real-world treatment patterns in patients with prurigo nodularis","volume":"82","author":"Huang","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/09546630903386606","article-title":"An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis","volume":"21","author":"Saraceno","year":"2010","journal-title":"J. Dermatol. Treat."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2310\/7750.2009.08082","article-title":"Update on intralesional steroid: Focus on dermatoses","volume":"14","author":"Richards","year":"2010","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000355671","article-title":"Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: Results of a randomized, hydrocortisone-controlled, double-blind phase II trial","volume":"227","author":"Siepmann","year":"2013","journal-title":"Dermatology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1067\/mjd.2001.110059","article-title":"Treatment of prurigo nodularis with topical capsaicin","volume":"44","author":"Stander","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.biopha.2017.11.124","article-title":"Research progress of capsaicin responses to various pharmacological challenges","volume":"96","author":"Patowary","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/bjd.17455","article-title":"Efficacy and safety of PAC-14028 cream\u2014A novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: A phase IIb randomized trial","volume":"180","author":"Lee","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jaci.2021.09.024","article-title":"Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD)","volume":"149","author":"Park","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1468-3083.2010.03865.x","article-title":"UVB 308-nm excimer light and bath PUVA: Combination therapy is very effective in the treatment of prurigo nodularis","volume":"25","author":"Hammes","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/ced.12365","article-title":"Prurigo nodularis: Retrospective study of 13 cases managed with methotrexate","volume":"39","author":"Spring","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jdv.14646","article-title":"Treatment of prurigo with methotrexate: A multicentre retrospective study of 39 cases","volume":"32","author":"Klejtman","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1610-0387.2008.06745.x","article-title":"Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: Results of a case series","volume":"6","author":"Siepmann","year":"2008","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaad.2018.02.024","article-title":"Rapid improvement of prurigo nodularis with cyclosporine treatment","volume":"78","author":"Wiznia","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1365-2133.1996.tb07964.x","article-title":"Nodular prurigo responsive to azathioprine","volume":"134","author":"Lear","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaad.2015.05.025","article-title":"Azathioprine treatment of intractable pruritus: A retrospective review","volume":"73","author":"Maley","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Zhai, L.L., Savage, K.T., Qiu, C.C., Jin, A., Valdes-Rodriguez, R., and Mollanazar, N.K. (2019). Chronic Pruritus Responding to Dupilumab-A Case Series. Medicines, 6.","DOI":"10.3390\/medicines6030072"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamadermatol.2018.3906","article-title":"Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis","volume":"155","author":"Mollanazar","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/jamadermatol.2018.3912","article-title":"Dupilumab Treatment for Generalized Prurigo Nodularis","volume":"155","author":"Beck","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/DER.0000000000000517","article-title":"Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis","volume":"31","author":"Napolitano","year":"2020","journal-title":"Dermatitis"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jdcr.2019.03.016","article-title":"Recalcitrant prurigo nodularis treated successfully with dupilumab","volume":"5","author":"Rambhia","year":"2019","journal-title":"JAAD Case Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/pde.14464","article-title":"Dupilumab for pediatric prurigo nodularis: A case report","volume":"38","author":"Fachler","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/1346-8138.16803","article-title":"The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study","volume":"50","author":"Fang","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1684\/ejd.2020.3947","article-title":"Dupilumab treatment of prurigo nodularis in an adolescent","volume":"31","author":"Giovannini","year":"2021","journal-title":"Eur. J. Dermatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1080\/09546634.2020.1853024","article-title":"Dupilumab in prurigo nodularis: A systematic review of current evidence and analysis of predictive factors to response","volume":"33","author":"Steinhoff","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaad.2021.02.038","article-title":"Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study","volume":"85","author":"Georgakopoulos","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jdin.2023.02.006","article-title":"Maintenance of response to dupilumab in prurigo nodularis: A retrospective cohort study","volume":"11","author":"Selvaraj","year":"2023","journal-title":"JAAD Int."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jaad.2023.04.056","article-title":"Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study","volume":"89","author":"Pezzolo","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: An expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","article-title":"JAK Inhibitors for Atopic Dermatitis: An Update","volume":"20","author":"He","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/bjd.21794","article-title":"Real-world data on the effectiveness, safety and drug survival of dupilumab: An analysis from the TREATgermany registry","volume":"187","author":"Stolzl","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: Pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies","volume":"151","author":"Thyssen","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdin.2023.06.005","article-title":"Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore","volume":"13","author":"Yew","year":"2023","journal-title":"JAAD Int."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/CCID.S354025","article-title":"Tofacitinib for Prurigo Nodularis: A Case Report","volume":"15","author":"Peng","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1111\/ijd.16568","article-title":"Successful treatment of prurigo nodularis with tofacitinib: The experience from a single center","volume":"62","author":"Liu","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/ced.14320","article-title":"Successful treatment of recalcitrant nodular prurigo with tofacitinib","volume":"45","author":"Molloy","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_186","first-page":"e106","article-title":"Treatment of chronic prurigo with upadacitinib: A case series","volume":"38","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e15642","DOI":"10.1111\/dth.15642","article-title":"Successful treatment of refractory prurigo nodularis with baricitinib","volume":"35","author":"Yin","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1111\/jdv.17991","article-title":"Improvement of chronic nodular prurigo with baricitinib","volume":"36","author":"Pereira","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e14878","DOI":"10.1111\/dth.14878","article-title":"Effectiveness of baricitinib in prurigo-type atopic dermatitis: A case report","volume":"34","author":"He","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4103\/idoj.idoj_508_22","article-title":"A Case of Recalcitrant Prurigo Nodularis with Heightened Expression of STAT 3 and STAT 6 and its Dramatic Response to Tofacitinib","volume":"14","author":"Agrawal","year":"2023","journal-title":"Indian Dermatol. Online J."},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Fakhraie, S., and Chovatiya, R. (2023). Janus Kinase Inhibition in the Treatment of Prurigo Nodularis. Dermatitis.","DOI":"10.1089\/derm.2023.0036"},{"key":"ref_192","first-page":"150","article-title":"Characterization of the effects on pruritus by novel treatments for atopic dermatitis","volume":"20","author":"Bonnekoh","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2340\/00015555-0553","article-title":"Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: Results of an open-labelled, two-arm proof-of-concept study","volume":"89","author":"Stander","year":"2009","journal-title":"Acta Derm. Venereol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ajd.12996","article-title":"Prurigo successfully treated with duloxetine hydrochloride","volume":"60","author":"Hashimoto","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_195","first-page":"115","article-title":"Amitriptyline\/Ketamine as therapy for neuropathic pruritus and pain secondary to herpes zoster","volume":"14","author":"Griffin","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/09546634.2019.1623369","article-title":"Tricyclic antidepressants for the treatment of chronic pruritus","volume":"32","author":"Boozalis","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaad.2016.02.1237","article-title":"Gabapentin and pregabalin for the treatment of chronic pruritus","volume":"75","author":"Matsuda","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"He, A., Alhariri, J.M., Sweren, R.J., Kwatra, M.M., and Kwatra, S.G. (2017). Aprepitant for the Treatment of Chronic Refractory Pruritus. BioMed Res. Int., 2017.","DOI":"10.1155\/2017\/4790810"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"Stander","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Stander, S., Siepmann, D., Herrgott, I., Sunderkotter, C., and Luger, T.A. (2010). Targeting the neurokinin receptor 1 with aprepitant: A novel antipruritic strategy. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010968"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/JLB.2AB1018-405R","article-title":"Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cells","volume":"106","author":"Ogasawara","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2015.09.039","article-title":"Thalidomide for the treatment of chronic refractory pruritus","volume":"74","author":"Sharma","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2340\/00015555-0997","article-title":"Efficacy of thalidomide in the treatment of prurigo nodularis","volume":"91","author":"Taefehnorooz","year":"2011","journal-title":"Acta Derm. Venereol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000331577","article-title":"Thalidomide in 42 patients with prurigo nodularis Hyde","volume":"223","author":"Andersen","year":"2011","journal-title":"Dermatology"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/exd.14669","article-title":"Role of kappa-opioid and mu-opioid receptors in pruritus: Peripheral and central itch circuits","volume":"31","author":"Kim","year":"2022","journal-title":"Exp. Dermatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2005.12.010","article-title":"Butorphanol for treatment of intractable pruritus","volume":"54","author":"Dawn","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_207","first-page":"533","article-title":"Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases","volume":"41","author":"Metze","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5021\/ad.2016.28.2.159","article-title":"Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus","volume":"28","author":"Lee","year":"2016","journal-title":"Ann. Dermatol."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Hawi, A., Alcorn, H., Berg, J., Hines, C., Hait, H., and Sciascia, T. (2015). Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol., 16.","DOI":"10.1186\/s12882-015-0043-3"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/jdv.17816","article-title":"Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open-label extension phase","volume":"36","author":"Weisshaar","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2340\/00015555-2593","article-title":"Efficacy of Body Lotion Containing N-palmitoylethanolamine in Subjects with Chronic Pruritus due to Dry Skin: A Dermatocosmetic Study","volume":"97","author":"Visse","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/09546634.2019.1639603","article-title":"Cannabinoids for the treatment of chronic refractory pruritus","volume":"32","author":"Khanna","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2020.01.036","article-title":"Cannabinoids for the treatment of chronic pruritus: A review","volume":"82","author":"Avila","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"606197","DOI":"10.3389\/fvets.2021.606197","article-title":"Polyphenols and Cannabidiol Modulate Transcriptional Regulation of Th1\/Th2 Inflammatory Genes Related to Canine Atopic Dermatitis","volume":"8","author":"Massimini","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1080\/08820139.2022.2083973","article-title":"The Effects of Cannabinoid Agonist, Heat Shock Protein 90 and Nitric Oxide Synthase Inhibitors on Increasing IL-13 and IL-31 Levels in Chronic Pruritus","volume":"51","author":"Ozyurt","year":"2022","journal-title":"Immunol. Investig."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000371890","article-title":"S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission","volume":"95","author":"Haruna","year":"2015","journal-title":"Pharmacology"},{"key":"ref_217","first-page":"80","article-title":"Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: A pilot study","volume":"15","author":"Pulvirenti","year":"2007","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2147\/CIA.S65448","article-title":"N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: Results of a randomized, double-blind, controlled study in 60 patients","volume":"9","author":"Yuan","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"ref_219","first-page":"801","article-title":"Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus","volume":"57","author":"Stander","year":"2006","journal-title":"Hautarzt"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","article-title":"Nemolizumab: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","article-title":"Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments","volume":"25","author":"Muller","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis","volume":"382","author":"Stander","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/jdv.18377","article-title":"Nemolizumab efficacy in prurigo nodularis: Onset of action on itch and sleep disturbances","volume":"36","author":"Stander","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ITT.S316602","article-title":"Immunotargets and Therapy for Prurigo Nodularis","volume":"11","author":"Labib","year":"2022","journal-title":"Immunotargets Ther."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"101826","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: A randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/all.13451","article-title":"Immunological and hematological effects of IL-5(Ralpha)-targeted therapy: An overview","volume":"73","author":"Hassani","year":"2018","journal-title":"Allergy"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMc2016395","article-title":"Benralizumab for Chronic Spontaneous Urticaria","volume":"383","author":"Bernstein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/all.14713","article-title":"Treatment of chronic spontaneous urticaria with benralizumab: Report of primary endpoint per-protocol analysis and exploratory endpoints","volume":"76","author":"Bernstein","year":"2021","journal-title":"Allergy"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jid.2021.10.006","article-title":"Neuron\u2013Mast Cell Cross-Talk in the Skin","volume":"142 Pt B","author":"Zhang","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/imr.12622","article-title":"Mast cell-neural interactions contribute to pain and itch","volume":"282","author":"Gupta","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/10\/5164\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:47Z","timestamp":1760107367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/10\/5164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":235,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25105164"],"URL":"https:\/\/doi.org\/10.3390\/ijms25105164","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}